Calyx focused on oral therapies for diabetes and inflammatory diseases, utilizing natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. Working with this company, Pappas Ventures expanded our expertise in oral therapies. Theracos acquired the company’s assets in 2003.